Luisa Hector
Stock Analyst at Berenberg Bank
(3.60)
# 2,001
Out of 4,411 analysts
288
Total ratings
57.5%
Success rate
4.9%
Average return
Main Sectors:
Stocks Rated by Luisa Hector
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintained: Buy | $275 | $222.47 | +23.61% | 18 | May 8, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Hold | CHF 340.00 | $324.00 | +4.94% | 52 | May 8, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €105.00 | $75.66 | +38.78% | 50 | May 6, 2026 | |
| LON: AZN AstraZeneca PLC | Rated: Buy | 17,000p | $13,284.00 | +27.97% | 69 | Mar 16, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 92.00 → CHF 110.00 | $119.70 | -8.10% | 4 | Mar 6, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $95 → $115 | $115.17 | -0.15% | 33 | Feb 27, 2026 | |
| LON: BTRW Barratt Redrow plc | Maintained: Hold | 414p | $255.10 | +62.29% | 1 | Feb 11, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Buy | kr 400.00 → kr 415.00 | $280.30 | +48.06% | 7 | Jan 16, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,660p | $1,950.00 | -14.87% | 7 | Jan 6, 2026 | |
| SNY Sanofi | Maintained: Buy | $63 → $67 | $44.05 | n/a | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $55 → $60 | $55.92 | n/a | 18 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $430.40 | n/a | 1 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €197.00 | $132.05 | n/a | 13 | Feb 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 | $26.04 | n/a | 1 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €77.50 | $36.01 | n/a | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $10.38 | n/a | 2 | Sep 15, 2016 |
AbbVie
May 8, 2026
Maintained: Buy
Price Target: $275
Current: $222.47
Upside: +23.61%
Roche Holding AG
May 8, 2026
Maintained: Hold
Price Target: CHF 340.00
Current: $324.00
Upside: +4.94%
Sanofi
May 6, 2026
Maintained: Buy
Price Target: €105.00
Current: $75.66
Upside: +38.78%
AstraZeneca PLC
Mar 16, 2026
Rated: Buy
Price Target: 17,000p
Current: $13,284.00
Upside: +27.97%
Novartis AG
Mar 6, 2026
Rated: Hold
Price Target: CHF 92.00 → CHF 110.00
Current: $119.70
Upside: -8.10%
Merck & Co.
Feb 27, 2026
Maintained: Hold
Price Target: $95 → $115
Current: $115.17
Upside: -0.15%
Barratt Redrow plc
Feb 11, 2026
Maintained: Hold
Price Target: 414p
Current: $255.10
Upside: +62.29%
Novo Nordisk A/S
Jan 16, 2026
Maintained: Buy
Price Target: kr 400.00 → kr 415.00
Current: $280.30
Upside: +48.06%
GSK plc
Jan 6, 2026
Maintained: Hold
Price Target: 1,660p
Current: $1,950.00
Upside: -14.87%
Sanofi
May 16, 2025
Maintained: Buy
Price Target: $63 → $67
Current: $44.05
Upside: n/a
Dec 10, 2024
Maintained: Hold
Price Target: $55 → $60
Current: $55.92
Upside: n/a
Feb 28, 2024
Upgraded: Buy
Price Target: n/a
Current: $430.40
Upside: n/a
Feb 10, 2022
Maintained: Hold
Price Target: €197.00
Current: $132.05
Upside: n/a
Jun 14, 2021
Maintained: Hold
Price Target: $43
Current: $26.04
Upside: n/a
Sep 11, 2018
Maintained: Hold
Price Target: €77.50
Current: $36.01
Upside: n/a
Sep 15, 2016
Reiterated: Hold
Price Target: n/a
Current: $10.38
Upside: n/a